ARCH-backed Sentivera launched with $1.5B in financing to develop treatments for inflammatory diseases, founded by the same team behind Metsera.
AUG 25, 2026
A U
A U.S. biotech newco founded by ARCH Venture Partners and Population Health Partners to develop, manufacture, and commercialize a licensed small-molecule immunology asset for type 2 inflammatory diseases. Sentivera holds rights outside Greater China; the asset received investigational new drug approval in China in August 2026.